Merck reports positive Phase III ONCEMRK trial of Isentress to treat HIV-1 infection

US-based pharmaceutical company Merck has reported positive results from its ongoing Phase III pivotal trial ONCEMRK of Isentress (raltegravir) to treat adults with HIV-1 infection.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news